Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Fintel reports that on May 6, 2025, Leerink Partners downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue ...

Vertex Pharmaceuticals (VRTX) and Neurocrine Biosciences (NBIX) shares are moving sharply after their respective earnings ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what ...

Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $450 to $459 on ...

Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.

VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $509.47, moving +1.19% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0 ...